Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Aspen Pharmacare Articles

Aduro BioTech buys all GVAX assets from BioSante; Aspen in talks to buy Merck unit

5 February 2013

South Africa's drugmakers bemoan low medicine price hikes

27 January 2013

Aspen Pharmacare acquires portfolio from GSK in Australia for £172 million

15 August 2012

Aspen and Adcock win South Africa preference tender

14 August 2012

Pierre Fabre gains approval for fibromyalgia drug Joncia in Australia; TGA cancels approval for four painkillers

22 November 2011

J&J unit Tibotec signs multiple deals with generic drugmakers for access to new HIV treatment rilpivirine pre-approval

31 January 2011

Aspen completes buyout of Sigma pharma business for $900 million

17 January 2011

Aspen Pharmacare to target Latin America for acquisitions; Full-year results

20 September 2010

Sigma finally accepts takeover bid from Aspen, but only for its pharma division, with a price tag of A$900 million

16 August 2010

Sigma Pharma tells suitor Aspen it wants a higher takeover offer

13 July 2010

Aspen confirms bid for Australia’s Sigma but, as expected, at a reduced A$0.55 per share

7 July 2010

Sigma Pharma slumps to a six-week low, as proposed buyer Aspen looks set to lower offer price for the firm

6 July 2010

South Africa’s Aspen confirmed as buyer of Sigma Pharma, with a $1.24 billion offer

24 May 2010

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS